

FreePress HOME > HEALTHCARE

# Meet the 30 young leaders who are forging a new future for the \$3.6 trillion healthcare industry

Lydia Ramsey Pflanzar, Kimberly Leonard, Megan Hembroth, Andrew Dunn, and Blake Dodge  
Oct 12, 2020, 9:49 AM



Courtesy of Lori Keams; Courtesy of Sabah Oney; Incredible Health; Buoy Health; Courtesy of Taison Bell; Samantha Lee/Business Insider

- Business Insider has selected the 30 leaders under 40 who are working to transform US healthcare.
- These business leaders, scientists, doctors, and entrepreneurs are confronting a pandemic and systemic racism in the industry.
- Those included are involved in everything from the development of coronavirus vaccines and treatments to new approaches to doctor's offices and women's health.
- For more stories like this, sign up here for Business Insider's daily healthcare newsletter.

Almost overnight, the coronavirus pandemic upended healthcare.

As the US learned to handle surges in COVID-19 cases that overwhelmed hospitals and shut down cities and confronted systemic racism amid protests sparked by the police killing of George Floyd, healthcare leaders have been navigating a new reality.

The people fueling the most change in 2020 have been not only business leaders and entrepreneurs but also scientists and healthcare workers on the front lines.

For their work, they've been named to Business Insider's list of the 30 leaders under 40 who are working to transform the \$3.6 trillion healthcare industry in the US.

The 30 people below were selected from hundreds of nominations, based on their potential to improve healthcare. The list is arranged alphabetically.

## Read on to meet the top young leaders transforming the future of healthcare.

*This article was first published on September 30.*

### Rich Horgan, 28, is writing a new playbook to treat ultrarare diseases with CRISPR, starting with helping his younger brother.



Rich Horgan started the nonprofit Cure Rare Disease. Rich Horgan

Terry Horgan has a muscle-wasting disease called Duchenne muscular dystrophy. While there are several experimental drugs being tried in DMD, Terry has an ultrarare genetic mutation that disqualifies him from those studies.

"What I found is that nothing under traditional drug development was going to help Terry," his older brother Rich Horgan said. "That scared me."

While Rich had no background in biotech, he started emailing muscle-disorder researchers after Terry suffered a serious fall in 2016. In 2018, Rich graduated from Harvard Business School and dedicated himself fully to a nonprofit he had set up called [Cure Rare Disease](#).

The immediate mission was to develop a treatment using the CRISPR gene-editing tool for his younger brother. That drug was designed in 2019, and some animal studies that finished in the spring delivered positive results, Rich said. The data hasn't yet been published.

The goal is to administer it to Terry in the first half of 2021 as an experimental treatment and work through regulatory steps with the Food and Drug Administration.

At this stage, Rich doesn't expect the treatment to be a miracle cure. But it could halt his brother's muscle-wasting disease and perhaps let him regain some upper body strength to do tasks like dressing himself, which can help him live longer and more independently.

The vision for Cure Rare Disease goes beyond Terry. Rich wants to create a nonprofit model to help patients with ultrarare diseases that are neglected by the drug industry.

Three other DMD patients are now in the nonprofit's pipeline behind Terry. Rich hopes to eventually expand to other diseases by plugging in new academic investigators.

"This message that families get of, 'Go home and love your kids; there's nothing you can do,' it literally just irritates the hell out of me because we can do something about it," Rich said.

— Andrew Dunn